Ligand Pharmaceuticals (LGND) Depreciation and Depletion (2012 - 2026)
Ligand Pharmaceuticals recorded quarterly Depreciation and Depletion of $119000.0 in Q1 2026, up 133.33% quarter-over-quarter from $51000.0 in Q4 2025, and down 76.8% year-over-year from $513000.0 in Q1 2025.
Ligand Pharmaceuticals' Depreciation and Depletion history runs 8 years deep, the most recent figure standing at $119000.0 for Q1 2026.
- In Q1 2026, Depreciation and Depletion fell 76.8% year-over-year to $119000.0; the TTM figure through Mar 2026 stood at $606000.0 (down 72.87% YoY), while the FY2025 annual figure was $1.0 million, down 56.52% from the prior year.
- Depreciation and Depletion came in at $119000.0 for Q1 2026 at Ligand Pharmaceuticals, up from $51000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $736000.0 in Q3 2024 to a low of $51000.0 in Q4 2025.
- A 3-year average of $379888.9 and a median of $389000.0 in 2024 frame the typical range for Depreciation and Depletion.
- On a YoY basis, Depreciation and Depletion climbed as much as 11.4% in 2025 and fell as far as 86.89% in 2025.
- Ligand Pharmaceuticals' Depreciation and Depletion stood at $389000.0 in 2024, then sank by 86.89% to $51000.0 in 2025, then surged by 133.33% to $119000.0 in 2026.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $119000.0, $51000.0, and $172000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn | 119,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119,000.00 |
| Mar 31, 2026 | 119,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | 172,000.00 |
| Sep 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 264,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Mar 31, 2025 | 513,000.00 |
| Dec 31, 2024 | 389,000.00 |
| Dec 31, 2024 | 389,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Jun 30, 2024 | 596,000.00 |
| Jun 30, 2024 | 596,000.00 |
| Mar 31, 2024 | 579,000.00 |
| Mar 31, 2024 | 579,000.00 |
| Jun 30, 2016 | 100,000.00 |
| Jun 30, 2016 | 100,000.00 |
| Mar 31, 2016 | 100,000.00 |
| Mar 31, 2016 | 100,000.00 |
| Sep 30, 2015 | 100,000.00 |
| Sep 30, 2015 | 100,000.00 |
| Mar 31, 2015 | 100,000.00 |
| Mar 31, 2015 | 100,000.00 |
| Sep 30, 2014 | 100,000.00 |
| Sep 30, 2014 | 100,000.00 |
| Jun 30, 2014 | 100,000.00 |
| Jun 30, 2014 | 100,000.00 |
| Mar 31, 2014 | 100,000.00 |
| Mar 31, 2014 | 100,000.00 |
| Dec 31, 2013 | 100,000.00 |
| Dec 31, 2013 | 100,000.00 |
| Sep 30, 2013 | 200,000.00 |
| Sep 30, 2013 | 200,000.00 |
| Jun 30, 2013 | 100,000.00 |
| Jun 30, 2013 | 100,000.00 |
| Mar 31, 2013 | 100,000.00 |
| Mar 31, 2013 | 100,000.00 |
| Dec 31, 2012 | 100,000.00 |
| Dec 31, 2012 | 100,000.00 |
| Sep 30, 2012 | 200,000.00 |
| Sep 30, 2012 | 200,000.00 |
| Jun 30, 2012 | 200,000.00 |
| Jun 30, 2012 | 200,000.00 |
| Mar 31, 2012 | 100,000.00 |
| Mar 31, 2012 | 100,000.00 |